OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
Form SC 13D/A Aerpio Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
-
Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
-
Form SC 13D Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Natera Reports Third Quarter 2020 Financial Results
-
Form 4 Galecto, Inc. For: Nov 02 Filed by: ORBIMED ADVISORS LLC
-
Petrichor Closes Oversubscribed Fund I at $410 Million
-
Edgewise Therapeutics Appoints John Moore as General Counsel
-
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
-
Form 3 Galecto Inc. For: Oct 28 Filed by: ORBIMED ADVISORS LLC
-
Steven Yecies Joins Javelin Oncology as Chief Executive Officer
-
5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
-
Form SC 13D/A BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business Officer
-
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Senior Corporate Executive Shelley Broader to its Board of Directors
-
Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer
-
Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A LogicBio Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock
-
Form SC 13D GRAYBUG VISION, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form 4 Xtant Medical Holdings, For: Oct 01 Filed by: ORBIMED ADVISORS LLC
-
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
-
Corvus Pharmaceuticals (CRVS) Announces Co-Founding of Angel Pharmaceuticals in China
-
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China
-
Arcutis Biotherapeutics Inc. (ARQT) Prices 4M Share Common Offering and Concurrent Private Placement
-
Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock
-
Xtant Medical Announces Closing of Debt Restructuring
-
Form 4/A Prelude Therapeutics For: Mar 27 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Prelude Therapeutics For: Sep 25 Filed by: ORBIMED ADVISORS LLC
-
Arcutis Bio (ARQT) Announces 4M Share Proposed Public Offering and Concurrent $35M Private Placement of Common Stock
-
Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock
-
Form 4 GRAYBUG VISION, INC. For: Sep 25 Filed by: ORBIMED ADVISORS LLC
-
Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
-
Form 3 GRAYBUG VISION, INC. For: Sep 24 Filed by: ORBIMED ADVISORS LLC
-
Form 3 Prelude Therapeutics For: Sep 24 Filed by: ORBIMED ADVISORS LLC
-
Form 4 89bio, Inc. For: Sep 21 Filed by: OrbiMed Advisors Israel II Ltd
-
Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions
-
Novellus Closes $57M Series C Financing
-
Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Adicet Bio, Inc. For: Sep 15 Filed by: ORBIMED ADVISORS LLC
-
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
-
Sinovac Reports Unaudited Second Quarter 2020 Financial Results

